PL3494133T3 - Receptory limfocytów t anty-kras-g12d - Google Patents
Receptory limfocytów t anty-kras-g12dInfo
- Publication number
- PL3494133T3 PL3494133T3 PL17749580.1T PL17749580T PL3494133T3 PL 3494133 T3 PL3494133 T3 PL 3494133T3 PL 17749580 T PL17749580 T PL 17749580T PL 3494133 T3 PL3494133 T3 PL 3494133T3
- Authority
- PL
- Poland
- Prior art keywords
- kras
- cell receptors
- receptors
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369883P | 2016-08-02 | 2016-08-02 | |
| PCT/US2017/044615 WO2018026691A1 (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3494133T3 true PL3494133T3 (pl) | 2022-11-21 |
Family
ID=59564253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17749580.1T PL3494133T3 (pl) | 2016-08-02 | 2017-07-31 | Receptory limfocytów t anty-kras-g12d |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US10611816B2 (pl) |
| EP (2) | EP3494133B1 (pl) |
| JP (4) | JP6993402B2 (pl) |
| KR (1) | KR102527052B1 (pl) |
| CN (2) | CN109790211B (pl) |
| AU (3) | AU2017306038B2 (pl) |
| DK (1) | DK3494133T3 (pl) |
| ES (1) | ES2928051T3 (pl) |
| HR (1) | HRP20221183T1 (pl) |
| HU (1) | HUE060121T2 (pl) |
| IL (2) | IL301894B2 (pl) |
| LT (1) | LT3494133T (pl) |
| PL (1) | PL3494133T3 (pl) |
| PT (1) | PT3494133T (pl) |
| RS (1) | RS63615B1 (pl) |
| SG (2) | SG10201913959WA (pl) |
| SI (1) | SI3494133T1 (pl) |
| SM (1) | SMT202200379T1 (pl) |
| WO (1) | WO2018026691A1 (pl) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3494133T3 (pl) * | 2016-08-02 | 2022-11-21 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptory limfocytów t anty-kras-g12d |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| EA202090652A1 (ru) | 2017-09-20 | 2020-08-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras |
| CA3077595A1 (en) | 2017-10-05 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for diagnosing, monitoring and treating neurological diseases and disorders |
| EP3810182A4 (en) | 2018-06-19 | 2022-08-24 | BioNTech US Inc. | Neoantigens and uses thereof |
| WO2020154617A1 (en) * | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| CN114026116A (zh) * | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| CN112760290A (zh) * | 2019-10-21 | 2021-05-07 | 郑州大学 | 携带突变的肿瘤驱动基因的干细胞及其用途 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| TW202132326A (zh) * | 2019-11-05 | 2021-09-01 | 美國德州系統大學評議委員會 | Hla限制性hormad1 t細胞受體及其用途 |
| CN115244173A (zh) | 2019-12-20 | 2022-10-25 | 英研生物(英国)有限公司 | 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途 |
| WO2021135178A1 (zh) * | 2019-12-30 | 2021-07-08 | 华夏英泰（北京）生物技术有限公司 | 一种增强型t细胞受体star及其应用 |
| US20230272038A1 (en) * | 2020-07-13 | 2023-08-31 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class ii-restricted drb t cell receptors against ras with g12d mutation |
| WO2022072760A1 (en) * | 2020-10-02 | 2022-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| WO2022109220A1 (en) * | 2020-11-20 | 2022-05-27 | Think Therapeutics, Inc. | Compositions and methods for optimized peptide vaccines |
| JP2023551819A (ja) * | 2020-11-25 | 2023-12-13 | ジーニアス・バイオテクノロジー・インコーポレイテッド | 抗原特異的ｔ細胞並びにその作製及び使用方法 |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| AU2022270361A1 (en) | 2021-05-05 | 2023-11-16 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| CN114920823B (zh) * | 2022-05-27 | 2023-10-17 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN119744173A (zh) * | 2022-07-22 | 2025-04-01 | 得克萨斯大学体系董事会 | 用于过继免疫疗法的具有增强功能的表达cd3的自然杀伤细胞 |
| CN115850444B (zh) * | 2022-09-15 | 2025-01-28 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN117777270B (zh) * | 2022-09-29 | 2025-04-25 | 广州医科大学 | 一种t细胞受体(tcr)及其用途 |
| AU2023397979A1 (en) * | 2022-12-13 | 2025-07-03 | Biontech Us Inc. | T cell receptor constructs and uses thereof |
| AU2024309123A1 (en) | 2023-06-28 | 2026-01-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
| CN120157754A (zh) * | 2023-12-14 | 2025-06-17 | 新景智源生物科技(苏州)有限公司 | Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞 |
| WO2025259799A2 (en) * | 2024-06-12 | 2025-12-18 | Biontech Us Inc. | T cell receptor compositions and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| US20020150891A1 (en) * | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
| US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| EP1545204B1 (en) | 2002-09-06 | 2016-08-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| EP2102236B1 (en) | 2007-01-12 | 2014-08-06 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | GP100-specific T cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| BR112013006718B1 (pt) | 2010-09-20 | 2021-12-07 | Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh | Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| EP3392270B1 (en) | 2011-09-15 | 2020-08-26 | The United States of America, as Represented by the Secretary Department of Health and Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| CN104080907A (zh) * | 2011-11-30 | 2014-10-01 | 日本国立癌症研究中心 | 诱导恶性干细胞 |
| HK1216231A1 (zh) * | 2013-06-03 | 2016-10-28 | Novartis Ag | Anti-pd-l1抗体及mek抑制剂及/或braf抑制剂的混合物 |
| GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| GB201314404D0 (en) | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| PT3223850T (pt) | 2014-11-26 | 2020-04-13 | Us Health | Receptores de células t anti-kras mutado |
| CN108350059B (zh) * | 2015-09-15 | 2021-10-08 | 美国卫生和人力服务部 | 识别hla-cw8限制性突变kras的t细胞受体 |
| PL3494133T3 (pl) * | 2016-08-02 | 2022-11-21 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptory limfocytów t anty-kras-g12d |
| AU2024309123A1 (en) | 2023-06-28 | 2026-01-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
-
2017
- 2017-07-31 PL PL17749580.1T patent/PL3494133T3/pl unknown
- 2017-07-31 IL IL301894A patent/IL301894B2/en unknown
- 2017-07-31 AU AU2017306038A patent/AU2017306038B2/en active Active
- 2017-07-31 KR KR1020197005837A patent/KR102527052B1/ko active Active
- 2017-07-31 HR HRP20221183TT patent/HRP20221183T1/hr unknown
- 2017-07-31 PT PT177495801T patent/PT3494133T/pt unknown
- 2017-07-31 RS RS20220894A patent/RS63615B1/sr unknown
- 2017-07-31 CN CN201780059356.4A patent/CN109790211B/zh active Active
- 2017-07-31 SG SG10201913959WA patent/SG10201913959WA/en unknown
- 2017-07-31 SI SI201731231T patent/SI3494133T1/sl unknown
- 2017-07-31 SM SM20220379T patent/SMT202200379T1/it unknown
- 2017-07-31 DK DK17749580.1T patent/DK3494133T3/da active
- 2017-07-31 CN CN202410214235.4A patent/CN118063591A/zh active Pending
- 2017-07-31 ES ES17749580T patent/ES2928051T3/es active Active
- 2017-07-31 LT LTEPPCT/US2017/044615T patent/LT3494133T/lt unknown
- 2017-07-31 EP EP17749580.1A patent/EP3494133B1/en active Active
- 2017-07-31 JP JP2019505220A patent/JP6993402B2/ja active Active
- 2017-07-31 HU HUE17749580A patent/HUE060121T2/hu unknown
- 2017-07-31 EP EP22182473.3A patent/EP4159751A1/en active Pending
- 2017-07-31 WO PCT/US2017/044615 patent/WO2018026691A1/en not_active Ceased
- 2017-07-31 US US16/321,899 patent/US10611816B2/en active Active
- 2017-07-31 SG SG11201900654QA patent/SG11201900654QA/en unknown
- 2017-07-31 IL IL264425A patent/IL264425B2/en unknown
-
2020
- 2020-04-02 US US16/838,395 patent/US11208456B2/en active Active
-
2021
- 2021-06-11 US US17/345,390 patent/US11897933B2/en active Active
- 2021-12-03 US US17/541,619 patent/US11840561B2/en active Active
- 2021-12-09 JP JP2021199878A patent/JP7413338B2/ja active Active
-
2023
- 2023-09-21 AU AU2023233125A patent/AU2023233125B2/en active Active
- 2023-12-27 JP JP2023221526A patent/JP7649370B2/ja active Active
-
2024
- 2024-01-25 US US18/423,020 patent/US12391742B2/en active Active
-
2025
- 2025-03-07 JP JP2025036871A patent/JP2025090690A/ja active Pending
- 2025-07-15 US US19/269,450 patent/US20250340611A1/en active Pending
-
2026
- 2026-01-15 AU AU2026200276A patent/AU2026200276A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3494133T3 (pl) | Receptory limfocytów t anty-kras-g12d | |
| DK3440105T3 (da) | T-cellereceptorer | |
| DK3440106T3 (da) | T-cellereceptorer | |
| IL262124A (en) | T cell receptors | |
| IL262146A (en) | T cell receptors | |
| PT3223850T (pt) | Receptores de células t anti-kras mutado | |
| DK3305266T3 (da) | Stiftformig stimulationsindretning | |
| EP4015404C0 (en) | STRAPPING DEVICE | |
| DK3404169T3 (da) | Gondolanordning | |
| DK3394094T3 (da) | T-celle receptorer specifikke for ny-eso-1 tumor antigen-hla-a*02 komplekset | |
| DK3448882T3 (da) | Anti-kk-lc-1-t-cellereceptorer | |
| EP3472208C0 (en) | T cell receptors and uses thereof | |
| DK3514172T3 (da) | Claudin-6-specifikke immunoreceptorer og t-celleepitoper | |
| DK4011339T3 (da) | Stomianordning | |
| DK3426850T3 (da) | Kabellægnings-indretning | |
| EP3529267C0 (en) | T CELL RECEPTOR | |
| LT3433270T (lt) | T ląstelių receptoriai | |
| DK3290073T3 (da) | Forbindelsesanordning | |
| EP3439798A4 (en) | SCREENING APPARATUS | |
| EP3551657A4 (en) | CHIMERIC CHLOROTOXIN RECEPTORS | |
| EP3453648C0 (de) | Zulaufvorrichtung | |
| DK3516155T3 (da) | Forbindelsesanordning | |
| ITUA20161802A1 (it) | Dispositivo reggipensile | |
| IL264855B1 (en) | T cell receptors and immune therapy using the same | |
| DK3504072T3 (da) | Sammenkoblingsindretning |